FarmaKology-Existing cancer drugs could become new Alzheimer’s treatments

Nov 17, 2021

FarmaKology-Existing cancer drugs could become new Alzheimer’s treatments

Today's Company

Jazz Pharmaceuticals

Jazz Pharmaceuticals , is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are focused on developing life-changing medicines for people with serious diseases—often with limited or no options—so they can live their lives more fully. By transforming biopharmaceutical discoveries into novel medicines, we are working to give people around the world the opportunity to redefine what’s possible – to make the “small wins” big again. Founded in 2003 and headquartered in Dublin, Ireland, Jazz Pharmaceuticals has a significant corporate presence in Palo Alto, CA, Philadelphia, PA and Oxford, England, with manufacturing facilities in Ireland and Italy. We maintain a highly collaborative culture where employees focus on how they can be successful and accomplish positive results by exemplifying the company’s core values: integrity, collaboration, passion, innovation and the pursuit of excellence. Together, we are more than 3,100 experts, analysts, specialists, advocates, scientists and professionals all with diverse backgrounds and perspectives. Working together, we are proud to support patients, innovate and bring new medicines to market.

News

Novavax Confirms European Medicines Agency Review of COVID-19 Vaccine Filing for Conditional Marketing Authorization

Novavax, Inc. , a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that European Medicines Agency has begun its evaluation of an application for conditional marketing authorization (CMA) for Novavax' COVID-19 vaccine, which will be marketed in the European Union under the brand name Nuvaxovid™.

European Commission approves Nucala (mepolizumab) in three additional eosinophil-driven diseases

GlaxoSmithKline today announced that the European Commission has approved Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5 (IL-5), for use in three additional eosinophil-driven diseases. This authorisation follows positive opinions recommended by the Committee for Medicinal Products for Human Use and authorises mepolizumab for use as an add on treatment in hypereosinophilic syndrome (HES), eosinophilic granulomatosis with polyangiitis (EGPA) and chronic rhinosinusitis with nasal polyps (CRSwNP).

GSK and Vir Biotechnology announce United States government agreements to purchase sotrovimab, a COVID-19 treatment

GlaxoSmithKline and Vir Biotechnology today announced US government contracts totalling approximately $1 billion to purchase sotrovimab, an investigational monoclonal antibody for the early treatment of COVID-19, which the US Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) in May 2021. GSK will supply these doses to the US government by December 17, 2021, enabling further expanded nationwide access to sotrovimab for patients.

Abintus Bio Enters Technology Agreement to Enhance In Vivo-Reprogrammed CAR Cell Potency and Durability Against Hematologic Malignancies and Solid Tumors

Abintus Bio, Inc. a company pioneering first-in-class, off-the-shelf medicines that reprogram cells directly in vivo, today announced that it has entered into an agreement with Memorial Sloan Kettering Cancer Center for the use of its next generation signaling technology (“1XX”) in Abintus’ In Vivo CAR-X products. These products have the potential to overcome the challenges of ex vivo CAR technologies and dramatically improve outcomes and access for patients with hematologic malignancies and solid tumors.